NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021.
Jennifer M. Weiss(University of Wisconsin–Madison), Mallory Campbell(Pancreatic Cancer Action Network), Priyanka Kanth(University of Utah), Rachel Hodan(Cancer Institute (WIA)), Michael J. Hall(Fox Chase Cancer Center), Heather Hampel(City of Hope), Arnold J. Markowitz(Memorial Sloan Kettering Cancer Center), David Shibata(St. Jude Children's Research Hospital), Susan Darlow(National Comprehensive Cancer Network), Bryson W. Katona(University of Pennsylvania), Xavier Llor(Yale Cancer Center), Carol A. Burke(Cleveland Clinic), Benjamin Swanson(The Ohio State University Wexner Medical Center), Olumide B. Gbolahan(University of Colorado Cancer Center), Brittany M. Szymaniak(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Lee-may Chen(Apple (Israel)), Sara Pirzadeh‐Miller(Southwestern Medical Center), William M. Grady(Seattle University), Gregory Idos(City Of Hope National Medical Center), Seth Felder(Moffitt Cancer Center), Katherine M Clayback(Roswell Park Comprehensive Cancer Center), Georgia L. Wiesner(The University of Western Australia), Samir Gupta(University of California San Diego), Susan Dallas, Mae Zakhour(Comprehensive Blood & Cancer Center), Laura W. Lamps(University of Michigan), Daniel C. Chung(Massachusetts General Hospital), Lisen Axell(University of Colorado Cancer Center), Andrew M. D. Wolf(Cancer Institute (WIA)), Francis M. Giardiello, Mary A. Dwyer(National Comprehensive Cancer Network), N. Jewel Samadder(Mayo Clinic), Matthew B. Yurgelun(Dana-Farber Cancer Institute)
Cited by 156
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k